Grifols, S.A.
Grifols operates as a plasma therapeutic company globally, providing various medical products including immunoglobulins, albumin, clotting factors, antithrombin III, and biological sealants. It also markets diagnostic testing equipment, reagents, and pharmaceutical products. The company is involved in research activities and develops new products, some of which are in clinical development stages.
Overview
Strengths
- High-quality earnings: over the last 6 years, free cash flow added up to 106% of reported net income.
- Valued below its Drug Manufacturers - General peers: P/E 12.8x vs. a median of 22.2x, P/FCF 8.2x vs. a median of 21.6x and EV/EBITDA 7.7x vs. a median of 13.9x.
- Resilient profitability: operating margin stayed between 11% and 18% in each of the last 6 years.
- Consistent growth: revenue has compounded at 7.1% a year over 5 years, rising in 4 of them.
- Cheaper than its own history: P/E 12.8x vs. a historical average of 65.6x, P/FCF 8.2x vs. a historical average of 41.0x and EV/EBITDA 7.7x vs. a historical average of 11.6x.
Weaknesses
- High leverage: net debt is 4.6x EBITDA, against a median of 1.1x for its Drug Manufacturers - General peers.
- Heavy interest burden: interest expense absorbs 48% of operating profit.
- Our discounted cash flow target price (3.50 USD) is 59% below the current price.
- ROIC of 7.6% trails 89% of its 27 Drug Manufacturers - General peers (median 19.1%).
Key Financial Data